Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: campbell j. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. Barber LJ, et al. Among authors: campbell j. J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140. J Pathol. 2013. PMID: 23165508
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Ang JE, et al. Among authors: campbell j. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. Clin Cancer Res. 2013. PMID: 23922302
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ. Campbell J, et al. Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3. Cell Rep. 2016. PMID: 26947069 Free PMC article.
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Miller RE, et al. Among authors: campbell j. Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30. Mol Cancer Ther. 2016. PMID: 27364904
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.
Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ. Pettitt SJ, et al. Among authors: campbell j. Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20. Sci Data. 2017. PMID: 28248920 Free PMC article.
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Dréan A, et al. Among authors: campbell j. Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15. Mol Cancer Ther. 2017. PMID: 28619759 Free PMC article.
ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ. Jones SE, et al. Among authors: campbell j. Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16. Cancer Res. 2017. PMID: 29038346 Free PMC article.
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ. Bajrami I, et al. Among authors: campbell j. Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603. Cancer Discov. 2018. PMID: 29610289 Free PMC article.
8,426 results